Taking Xeljanz? A new safety warning

Newly released safety trial results have revealed heart and cancer risks associated with Xeljanz, a common treatment for rheumatoid arthritis (RA) and ulcerative colitis. The long-term study, a condition  of the medication’s initial approval, was recently completed.   What is Xeljanz? “XELJANZ is a Janus kinase (JAK) inhibitor that helps Read more…

en_USEnglish